Cell Therapeutics’ Pixantrone to Be Reviewed by FDA

Cell Therapeutics, Inc. announced Thursday that on February 10, 2010 the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee will review the New Drug Application for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin’s lymphoma.
StreetInsider